India and the Middle East stand out as dynamic pharma markets, each offering unique strengths for strategic partnerships and business growth.
India: The World’s Pharmacy Powerhouse
- Supplies 40% of US generic drugs and 25% in the UK
- Sizeable global biosimilar market for Indian companies with over US$ 20B biologics losing patent protection
- Leading CDMO sector with rapid growth and strong government incentives
- Massive domestic market projected to reach USD 130B by 2030
- Digital health revolution through the Ayushman Bharat Digital Mission
- Emerging hub for rare diseases and orphan therapies with innovative access models
Middle East: Premium Access & Innovation Hub
- High demand for chronic and specialty care, including diabetes and oncology
- Markets expected to grow from USD 40B to USD 58B by 2030 with strong government reimbursement
- Localization push aligned with Saudi Vision 2030 and UAE biotech investments
- Dual-market strategy: competitive tenders and specialty-driven private care
- Rapid adoption of clinical trials and AI-powered health technologies
SAI has developed a complimentary short executive briefing on the topic. For a copy of this document or to discuss how SAI may support your business, please contact us at saibd@saiasia.com .